Nccn Guideline Updates News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia.

Women healthDigital healthPopulation healthNccn guideline updatesJak inhibitorsRare diseases